WallStSmart

Elutia Inc. (ELUT)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 288552% more annual revenue ($35.48B vs $12.29M). MDT leads profitability with a 13.0% profit margin vs 4.3%. MDT earns a higher WallStSmart Score of 56/100 (C).

ELUT

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 3.0Value: 5.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ELUT.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELUT2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.2%8/10

16.2% revenue growth

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

ELUT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$47.06M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
4.3%3/10

4.3% margin — thin

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ELUT

The strongest argument for ELUT centers on Price/Book, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : ELUT

The primary concerns for ELUT are EPS Growth, Market Cap, Return on Equity. Thin 4.3% margins leave little buffer for downturns.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

ELUT profiles as a growth stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.73 — expect wider price swings.

ELUT is growing revenue faster at 16.2% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 43/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elutia Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?